<DOC>
	<DOCNO>NCT00331721</DOCNO>
	<brief_summary>The main objective study investigate tolerability enecadin patient acute ischemic stroke . Furthermore , pharmacokinetics enecadin male female patient acute ischemic stroke assess . Efficacy trend evaluate day 30 post stroke .</brief_summary>
	<brief_title>Tolerability Enecadin ( INN ) Acute Ischemic Stroke Trial - TEST</brief_title>
	<detailed_description>In acute stage ischemic stroke , ischemic core characterize marked decrease blood flow present , lead irreversible neuronal damage early stage . Around boundary ischemic core , region call ischemic penumbra functional recovery possible recirculation blood flow within several hour onset , even though blood flow markedly decrease . Prevention nerve cell death ischemic penumbra neuroprotective therapy greatly improve outcome prognosis acute ischemic stroke .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<criteria>Patients acute ischemic stroke ( score 320 National Institutes Health Stroke Scale [ NIHSS ] ) level consciousness score : 0 1 ( conscious patient ) eligible treat within 9 hour onset stroke symptom . For female patient : postmenopausal surgically sterile ( postmenopausal : age ≥55 year last menses ≥3 year ago ) . Participation investigational study previous 30 day . Patients unable understand trial relate information . History evidence severe heart disease specify protocol . History evidence additional disease result baseline visit specify protocol . Use concomitant prior medication define protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Acute Ischemic Stroke</keyword>
</DOC>